Cosmos Health shares surge 13.23% after-hours after expanding C-Scrub availability at UK's Tesco and Superdrug.
ByAinvest
Wednesday, Feb 18, 2026 4:16 pm ET1min read
COSM--
Cosmos Health surged 13.23% in after-hours trading following the announcement that its antimicrobial skin cleanser, C-Scrub, is now available at Tesco, the UK’s largest retailer, and Superdrug, the UK’s second-largest beauty and health retailer. These partnerships significantly expand C-Scrub’s retail footprint, enhancing its visibility, accessibility, and credibility in the UK market. The CEO highlighted that securing placements with these major retailers strengthens Cosmos Health’s market positioning and provides a platform for future product rollouts in Europe. The dual expansion into Tesco and Superdrug underscores the company’s strategic retail growth in the UK, aligning with the stock’s upward movement.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet